A Phase 1b Study of PU-H71 With Nab-paclitaxel (Abraxane) in Patients With HER2-Negative Metastatic Breast Cancer

Trial Profile

A Phase 1b Study of PU-H71 With Nab-paclitaxel (Abraxane) in Patients With HER2-Negative Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 May 2017

At a glance

  • Drugs PU H71 (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 23 May 2017 Status changed from planning to recruiting.
    • 06 Apr 2017 New trial record
    • 30 Mar 2017 According to a Samus Therapeutics media release, the company expects to initiate this trial in early second quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top